Subject(s)
Carcinoma, Basal Cell , Carcinoma, Squamous Cell , Melanoma , Neoplasms, Basal Cell , Skin Neoplasms , Carcinoma, Basal Cell/diagnosis , Carcinoma, Basal Cell/pathology , Carcinoma, Basal Cell/therapy , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Humans , Melanoma/diagnosis , Melanoma/pathology , Melanoma/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Skin Neoplasms/therapySubject(s)
Behavior, Addictive/psychology , Sunbathing/classification , Sunbathing/psychology , Suntan/physiology , Biomedical Research , Diagnostic and Statistical Manual of Mental Disorders , Health Knowledge, Attitudes, Practice , Humans , Mental Disorders/therapy , Ultraviolet Rays/adverse effectsABSTRACT
Primary intranasal basal cell carcinoma (BCC) is a rare tumour that presents a therapeutic challenge. Here we present two cases illustrating the lateral alarotomy to gain access to an isolated BCC involving only the intranasal lining. Successful intranasal access was achieved in both cases using the alarotomy technique. We also review other methods of repair for the isolated intranasal lining defect. The presentation of intranasal BCC purely as an isolated entity without cutaneous involvement is rare, and our surgical approach via alarotomy allows optimum visibility for tumour resection.
Subject(s)
Carcinoma, Basal Cell/surgery , Mohs Surgery/methods , Neoplasm Recurrence, Local/surgery , Nose Neoplasms/surgery , Skin Neoplasms/surgery , Aged, 80 and over , Humans , Male , Middle Aged , Skin Transplantation/methods , Treatment OutcomeABSTRACT
BACKGROUND: There is a small subset of locally advanced nonmetastatic cutaneous squamous cell carcinoma (cSCC) for which local therapy is not curative or feasible, making systemic therapy a possible treatment option. OBJECTIVES: To calculate overall response rates (ORR), median time to response (TTR) and median duration of response (DOR) of locally advanced nonmetastatic cSCC to systemic therapy [targeted agents, biological response modifiers (BRM) and chemotherapy]. PATIENTS AND METHODS: Medline and PubMed were searched for reports of nonmetastatic locally advanced cSCC treated with systemic therapy from 1970 to 2011. No limits were placed on study design. ORR, TTR and DOR were calculated for systemic therapy overall and for each treatment category. RESULTS: Twenty-eight observational studies yielded 119 patients for analysis. The ORR for systemic therapy was 72% (TTR 9 weeks, DOR 42 weeks). Targeted therapy and BRM achieved ORR of 100% (TTR 12 weeks, DOR 20 weeks) and 86% (TTR 10 weeks, DOR 20 weeks), respectively, and oral chemotherapy, intravenous chemotherapy and intra-arterial chemotherapy achieved ORR of 20% (TTR 10 weeks, DOR 24 weeks), 68% (TTR 3 weeks, DOR 44 weeks) and 100% (TTR 15 weeks, DOR 112 weeks), respectively. A limitation of this study was that no controlled data were identified and sample sizes were small. CONCLUSIONS: Systemic treatment leads to objective responses in locally advanced cutaneous SCC that are not amenable to local cure.
